Diadem Biotherapeutics is based in Los Angeles, CA. The company's founders were located at the IndieBio accelerator in San Francisco through January 2020. Diadem Biotherapeutics develops shelf-stable, engineered exosomes for the anti-inflammatory market, including the disease Chronic obstructive pulmonary disease (COPD). The company is also developing medicines for metabolic and autoimmune diseases. Diadem is focused on biotherapeutic materials produces through biological methods such as recombinant DNA technology. Diadem Biotherapeutics is engineering inhalable exosomes that act as immune modulators.
The company is developing a SARS-CoV-2 (COVID-19) vaccine using engineering exosomes as the antigen. The exosome will be engineered to have surface bound SARS-CoV-2 proteins and immune-stimulating ligands, so that they are similar to non-replicative virus-like particles. Immune stimulating ligands such as 4-1BB may be engineered onto the exosomes as well to increase immune response and memory for the SARS-CoV-2 antigen.
Co-Founder, CEO, Board Member
Co-Founder, CTO, Board Member
Documentaries, videos and podcasts
- Cluster: BiotechnologyA cluster of topics related to biotechnology.
- Cluster: COVID-19A cluster of topics related to COVID-19. COVID-19 is the abbreviated name for coronavirus disease 2019, a respiratory disease caused by a novel coronavirus strain called SARS-CoV-2. COVID-19 was first detected in Wuhan City, China and the outbreak was declared a pandemic on March 11, 2020 by the WHO.